Aghajanian C - Search Results

1

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Moore K, et al. Among authors: aghajanian c. N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21. N Engl J Med. 2018. PMID: 30345884 Clinical Trial.

2

Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.

Sabbatini P, Aghajanian C, Leitao M, Venkatraman E, Anderson S, Dupont J, Dizon D, O'Flaherty C, Bloss J, Chi D, Spriggs D. Sabbatini P, et al. Among authors: aghajanian c. Clin Cancer Res. 2004 May 1;10(9):2962-7. doi: 10.1158/1078-0432.ccr-03-0486. Clin Cancer Res. 2004. PMID: 15131031 Clinical Trial.

3

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D. Sabbatini P, et al. Among authors: aghajanian c. J Clin Oncol. 2004 Nov 15;22(22):4523-31. doi: 10.1200/JCO.2004.12.043. J Clin Oncol. 2004. PMID: 15542803 Clinical Trial.

4

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Gordon MS, et al. Among authors: aghajanian c. J Clin Oncol. 2006 Sep 10;24(26):4324-32. doi: 10.1200/JCO.2005.05.4221. Epub 2006 Aug 8. J Clin Oncol. 2006. PMID: 16896006 Clinical Trial.

5

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P. Juretzka MM, et al. Among authors: aghajanian c. Gynecol Oncol. 2007 Jan;104(1):176-80. doi: 10.1016/j.ygyno.2006.07.027. Epub 2006 Sep 25. Gynecol Oncol. 2007. PMID: 16996584

6

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Harrison ML, et al. Among authors: aghajanian c. Gynecol Oncol. 2007 Sep;106(3):469-75. doi: 10.1016/j.ygyno.2007.05.008. Epub 2007 Jul 5. Gynecol Oncol. 2007. PMID: 17614127 Free PMC article.

7

A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.

Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, Lewin S, Konner J, Derosa F, Spriggs D, Iasonos A, Sabbatini P. Levine D, et al. Among authors: aghajanian c. Cancer. 2007 Dec 1;110(11):2448-56. doi: 10.1002/cncr.23072. Cancer. 2007. PMID: 17918264 Free article. Clinical Trial.

8

Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.

Zivanovic O, Barakat RR, Sabbatini PJ, Brown CL, Konner JA, Aghajanian CA, Abu-Rustum NR, Levine DA. Zivanovic O, et al. Cancer. 2008 Jun 15;112(12):2690-7. doi: 10.1002/cncr.23485. Cancer. 2008. PMID: 18428210 Free article.

9

Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.

Kehoe SM, Williams NL, Yakubu R, Levine DA, Chi DS, Sabbatini PJ, Aghajanian CA, Barakat RR, Abu-Rustum NR. Kehoe SM, et al. Gynecol Oncol. 2009 May;113(2):228-32. doi: 10.1016/j.ygyno.2009.01.016. Epub 2009 Feb 28. Gynecol Oncol. 2009. PMID: 19254808

10

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR. Chi DS, et al. Among authors: aghajanian c. Gynecol Oncol. 2009 Jul;114(1):26-31. doi: 10.1016/j.ygyno.2009.03.018. Epub 2009 Apr 23. Gynecol Oncol. 2009. PMID: 19395008

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

302 results

Search Page